UK +44 (0)1865 849841
Malaysia +60 3 2117 5193

Precision Medicine

Digital pathology and Artificial Intelligence in the precision medicine era

In 2017, technological advances in cloud computing and artificial intelligence has pathology positioned to become one of the most talked about medical fields in healthcare.

Read More

Considerations for the development of a liquid biopsy assay for cancer

Non-invasive evaluation of molecular markers has shifted from the realm of prenatal diagnosis to tracking the effect of cancer treatment and management. 

Read More

Precision medicine: the solution to the largest inefficiency in healthcare systems

Rheumatoid arthritis is one of the highest sources of the inefficiency of worldwide health care systems. This could be avoided by more tailored and individualised therapeutic strategies which require better molecular characterization of each patient.

Read More

Is the age of invention over?

At the dawn of the last century, people who were heralded as world-changers were a different breed. Edison, Franklin (and let’s also put Tesla here, though his contributions weren’t recognized at the time), Turing, Neumann, and a lot of other great people. Things are different now. The people we idolize today are the innovators – Jobs, Musk, Page&Brin – the Great Communicators who can drive products to the market, and carve out a viable market strategy despite the strong competition, or create entirely new markets.

Read More

Precision Medicine: An open letter from Miro Venturi

Dear Colleagues,

In recent times, we have seen advances in precision medicine lead to powerful discoveries and improved patient care. Liquid biopsies for example, now have the potential to be a real game-changer in cancer testing and could revolutionise cancer care.

Read More

The future of precision medicine

Unreasonable cost of trial-and-error medicine means precision medicine is imperative for targeted therapies

Rising pressures to decrease healthcare cost globally, the emergence of value-based reimbursement models and healthcare digitisation trends are transitioning the medication model from ‘one-size-fits-all’ to stratified and outcome based targeted therapies.

Read More

Upcoming Developments in Precision Medicine

Future of immunotherapies

Immunotherapies are on the fast growth trajectory which will be moderated based on responder groups, toxicity and efficacy results and high costs and increasingly used in combination therapies. The overall immune oncology checkpoint inhibitor market was over $2.0 billion and is set to grow to $14 billion by 2018.

Read More

Presidents, Rock Stars and Companion Diagnostics

President Jimmy Carter announced last spring that he no longer needed treatments for the metastatic melanoma found in his brain – after treatment with pembrolizumab (Keytruda, Merck), his physicians could no longer detect the cancer.

Read More

Subscribe to Our Newsletter

Get free reports and resources from our world class speakers.
  • This field is for validation purposes and should be left unchanged.

Archive